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Abstract 
 
Nephrocalcinosis describes the ectopic deposition of calcium salts in the kidney 
parenchyma. Nephrocalcinosis can result from a number of acquired causes, but also 
an even greater number of genetic diseases, predominantly renal, but also extra-renal. 
Here we provide a review of the genetic causes of nephrocalcinosis, along with 
putative mechanisms, illustrated by human and animal data. 
 
  
4 
 
Introduction 
The term Nephrocalcinosis was first coined by the then physician’s assistant Fuller 
Albright in 1934 [2]. Albright was referring to calcium deposition into the kidney of 
patients with primary hyperparathyroidism usually associated with impaired kidney 
function. Currently the term is often used to describe calcium deposition that is seen 
in the kidneys radiologically which, as we will discover later, does not necessarily 
constitute nephrocalcinosis as Albright originally meant it. The calcium is in the form 
of either calcium phosphate or calcium oxalate; some have termed the latter oxalosis, 
but here we shall use the term nephrocalcinosis to cover both. In the majority of cases 
the underlying event leading to nephrocalcinosis is hypercalciuria. This may be the 
result of extra-renal conditions leading to an increased calcium load  with subsequent 
hypercalciuria; for example enhanced absorption of calcium in the gut. Alternatively, 
hypercalciuria may be caused by impaired renal handing of calcium. Here, we explore 
the genetic, pathophysiological and clinical aspects of both renal and extra-renal 
diseases leading to nephrocalcinosis.  
Types of Nephrocalcinosis 
Oliver Wrong proposed dividing nephrocalcinosis into three different types [78]. The 
first was molecular nephrocalcinosis, in which there is an increase in renal intracellular 
calcium but no crystal formation; in essence reflecting the renal dysfunction of 
hypercalcemia. The second was microscopic nephrocalcinosis, in which calcium 
phosphate or oxalate crystals could be identified on light microscopy but not 
radiologically (as often happens in biopsies of renal tissue with acute tubular necrosis). 
The third was macroscopic nephrocalcinosis, where the calcium salt is visible 
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radiologically. It is this third type that is typically referred to by the term 
nephrocalcinosis, and is also the type that we will mainly consider here. 
Sites of Nephrocalcinosis 
Cortical nephrocalcinosis is rare (2.4% of the largest published series [116]) and 
usually results from severe destructive disease of the cortex. This has been described 
in chronic glomerulonephritis (although this is often in the presence of another factor, 
e.g. increased calcium ingestion) [4], acute cortical necrosis [22], chronic 
pyelonephritis (which may be focal and therefore asymmetric) [31] and trauma [16]. 
Medullary nephrocalcinosis is the usual distribution seen, perhaps unsurprising 
considering the location of the major homeostatic pathway of Ca2+ reabsorption (the 
thick ascending limb of the loop of Henle) and the segment involved with acid base 
regulation (the collecting duct). 
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Genetic Aspects of Nephrocalcinosis 
A number of monogenetic conditions lead to nephrocalcinosis. Over the last few 
decades we have been able to classify the genetic basis of a number of conditions 
causing nephrocalcinosis and these will form the focus of this review.  
 
Renal genetic disease causing Nephrocalcinosis 
 
Proximal Tubule 
Dent Disease and Lowe Syndrome 
The term Dent disease was first coined by Wrong in 1994 based on the phenotype 
first described by Dent in the 1960s [26,117]. It is an X-linked recessive disorder 
characterized by the renal Fanconi syndrome (low-molecular weight proteinuria, 
aminoaciduria, phosphaturia, uricosuria, glycosuria) hypercalciuria, nephrocalcinosis 
and nephrolithiasis. It also causes progressive renal impairment with ESRF out of 
keeping with the degree of nephrocalcinosis, often in the 4th to 5th decade. Dent 
disease (Dent-1) is caused by mutations of CLCN5 gene that encodes the chloride 
transporter CIC-5. ClC-5 is found in endosomes involved in the endocytic reabsorption 
of low molecular weight (LMW) proteins. 40% of patients with Dent disease do not 
have CLCN5 mutations; of these, about a third have a mutation in OCRL, these 
patients are referred to as Dent-2 [45].   
Lowe syndrome, which is caused by OCRL mutations, has the same renal phenotype 
as Dent disease in addition to congenital cataracts and mental impairment [10]. There 
is some overlap between Dent-2 and Lowe syndrome but Dent-2 sufferers tend to 
have mild or absent oculocerebral symptoms [11]. 
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Loss of CLC-5 leads to impaired lysosomal trafficking to the lumen. As endocytosis is 
required for reabsorption of proteins in the proximal tubule this will interfere with 
normal function. ClC-5 is strongly expressed in proximal tubular cells, where it is 
collocated with vacuolar H+ATPase in endosomes, which are involved in reabsorption 
of filtered albumin and low molecular weight proteins. Inactivation of ClC-5 in rodents 
leads to a severe endosomal trafficking defect, resulting in a loss of the multiligand 
cubulin and megalin proteins from the proximal tubular cell brush border, and shedding 
of these proteins into the urine as well as impaired lysosomal processing . 
The pathophysiology of hypercalciuria in Dent/Lowe has not been clearly delineated. 
It has been suggested that decreased absorption of phosphate and vitamin D binding 
protein in the proximal tubule leads to secondary increases in Vitamin D3 synthesis 
resulting in hypercalcemia and then hypercalciuria [27]. Another proposed mechanism 
is that decreased chloride reabsorption in the proximal tubule leads to reduced calcium 
absorption in downstream nephron segments (presumably by reducing the trans-
tubular electrochemical gradient necessary for cation transport) [103]. 
Nephrocalcinosis may occur in Dent patients without hypercalciuria [66] and there is 
some evidence that defective ClC-5 in collecting duct cells may cause decreased 
clearing of calcium crystals from the apical cell surface [87]. Also, decreased proximal 
tubular endocytosis of parathyroid hormone (PTH), results in an increased luminal 
concentration of PTH, which stimulates increased 1-alfa hydroxylation and causes 
decreased expression of NaPi2 at the apical membrane and phosphaturia, favouring 
calcification [81]. 
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Idiopathic infantile hypercalciuria (IIH) and hereditary hypophosphatemic rickets with 
hypercalciuria (HHRH) 
Pathogenic NaPi2a variants, caused by mutations in SLC34A1 can cause autosomal 
recessive IIH, characterised by hypophosphatemia and nephrocalcinosis [89]. Some 
variants may have a full renal Fanconi syndrome [67]. 
Homozygous mutations of SLC34A3 which encode NaPi2c can cause HHRH, causing 
hypophosphatemia, secondary elevation of 1,25 OH vitamin D and hypercalciuria and 
osteomalacia. Heterozygous carriers get a similar but less severe phenotype; both 
homozygotes and heterozygotes are more likely than wild type to develop medullary 
nephrocalcinosis [25]. NaPi2a deletion in mice causes interstitial deposition of CaPi, 
associated with phosphate wasting, a secondary elevation in 1,25 OH Vitamin D and 
subsequent hypercalcemia and hypercalciuria [19]. 
 
Fanconi Bickel syndrome  
Fanconi Bickel syndrome is caused by mutations in SLC2A2 which encodes the 
glucose transporter GLUT2 [68]. This is responsible for transcellular glucose transport 
in enterocytes as well as proximal renal tubular cells. Pathogenic mutations in this 
gene cause a glycogen storage disorder resulting in generalized proximal tubular 
dysfunction. Hypercalciuria is present, as well as hyperphosphaturia; this is thought to 
be because pathogenic GLUT2 mutations may cause decreased expression of NaPi2c 
in proximal tubular cells [68]. 
 
Loop of Henle  
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Bartter Syndromes 
The Bartter syndromes comprise a group of autosomal recessive disorders caused by 
mutations in a number of genes characterized by salt wasting in the thick ascending 
limb of the loop of Henle, resulting in low-normal blood pressure, hypokalemic 
metabolic alkalosis, and hypercalciuria. Hypercalciuria is responsible for the 
nephrocalcinosis often seen in this condition [88]. 
The genetic basis for the condition is well delineated and is due to mutations in 
different TAL transporter proteins. Bartter I is due to mutations of SLC12A1 that 
encodes the NKCC2 cotransporter itself [93]. Bartter II is due to mutations in KCNJ1 
which encodes the apical ROMK potassium channel [94] and Bartter syndrome type 
III is due to mutations of CLCNKB encoding the chloride channel ClCKb on the 
basolateral membrane [92]. These channels are required for apical potassium and 
basolateral chloride efflux and for NKCC2 function. Mutations of BSND which encodes 
Barttin, a chaperone protein that is necessary for the correct insertion of ClCNKA and 
ClCNKB in the basolateral membrane are responsible for Bartter IV [33]. Barttin also 
acts in the epithelium of the inner ear and patients with Bartter syndrome type IV have 
sensorineural deafness. Finally, there are rare gain of function mutations of the 
calcium sensing receptor (CaSR), that can lead to a Bartter-like phenotype [110]; this 
has also been termed Bartter V. Activation of the CaSR causes inactivation of NKCC2 
probably via inhibition of ROMK [109]. This may also partly explain the diuresis 
commonly seen in hypercalcaemic states. Nephrocalcinosis has been reported in all 
five types of Bartter syndrome but is a prominent feature in types I, II, and V. 
 
Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC) 
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This is a rare autosomal recessive condition characterized by severe 
nephrocalcinosis, nephrolithiasis and progressive renal failure. Defects in two genes 
have been found, CLDN16 [95] and CLDN19 [58] which encode Claudin-16 and 
Claudin-19 respectively. These proteins are tight junction components crucially 
involved in the paracellular absorption of calcium and magnesium in the TAL. The 
pathogenic mutations cause the tight junctions to lose cation selectivity, which allows 
leakage of anions into the lumen, diminishing the positive lumen potential required to 
drive the paracellular absorption of calcium and magnesium [48]. The resulting heavy 
hypercalciuria causes severe nephrocalcinosis and is associated with subsequent 
renal failure [73]. 
 
Insulin Receptor Mutations 
Hypercalciuria and nephrocalcinosis has been reported in cases of insulin receptor 
mutations [96]. These autosomal recessive mutations of INSR lead to severe insulin 
resistance with subsequent hyperinsulinism. The cause of the hypercalciuria has not 
been delineated, but mirrors the hypercalciuria that occurs with diabetes, which is 
reversible by insulin, suggesting a role of INSR activation in the regulation of urinary 
calcium excretion [85]. The patients were also found to have hypermagnesuria and 
hypokalemic metabolic alkalosis. INSR is expressed throughout the nephron, and the 
mechanism of INSR mutations in causing nephrocalcinosis is not clear; the association 
of hypercalciuria and hypermagnesuria suggests a lesion in the TAL or DCT.  
 
Distal Tubule 
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Approximately 7-10% of the filtered calcium is reabsorbed in the distal convoluted 
tubule (DCT). Uniquely, this Ca2+ transport is transcellular and active. Surprisingly, 
there are no known monogenetic conditions arising from this segment causing 
nephrocalcinosis [101].  
 
Familial Hyperkalemic Hypertension (FHHt) 
FHHt causes hypertension, hyperkalemia, metabolic acidosis and hypercalciuria. It is 
caused by mutations of the kinases, WNK1 and WNK4 [111], as well as the ubiquitin 
ligase Cullin 3 [12] and its adaptor Kelch-like 3 [65]. These pathogenic mutations 
increase the phosphorylation and activity of the sodium chloride cotransporter. 
Hypercalciuria is a particular feature of FHHt due to WNK4 mutations; possibly as 
WNK4 appears to enhance TRPV5 Ca2+ transport, and this effect is attenuated with 
pathogenic WNK4 mutations [53]. Decreased proximal reabsorption in response to 
volume expansion is also likely, in contrast to the hypocalciuria of Gitelman syndrome 
or thiazide administration [75]. Although nephrolithiasis secondary to hypercalciuria 
has been reported in FHHt [100], to date nephrocalcinosis has not. 
 
Cortical collecting duct 
Distal Renal Tubular Acidosis (dRTA) 
This condition has a high propensity to cause nephrocalcinosis (80% of individuals) 
and accounts for 19% of all cases in Wrong’s series [116]. The chronic metabolic 
acidosis leads to phosphate being liberated from the skeleton to buffer acid; the 
mobilized calcium causes hypercalciuria. As calcium phosphate precipitates at a 
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higher pH, the alkaline urine will tend to favor the formation of calcium phosphate 
stones and/or nephrocalcinosis [40]. There may also be a lesser effect from an overt 
metabolic acidosis, which may contribute to hypercalciuria by decreasing expression 
of TRPV5 in the DCT [74]. dRTA is caused by a failure of the alpha-intercalated cells 
to acidify the urine. In these cells, CO2 is hydrated to form a bicarbonate ion and a 
proton in a reaction catalysed by carbonic anhydrase 2. The proton is extruded apically 
by the apical proton pump, vacuolar H+ATPase, while the bicarbonate is reclaimed to 
the systemic circulation by the chloride bicarbonate counter transporter anion 
exchanger 1 (AE1). Mutations of the gene SLC4A1, which encodes AE1 were 
proposed as a genetic cause of hereditary dRTA by Unwin and colleagues [103], and 
this was later proved correct [13]. Subsequently, mutations of ATP6V1B1 [54] or 
ATP6V0A4 [98] which encode the B1 and A4 subunits (respectively) of vH+ATPase 
were also shown to lead to dRTA. Deficiency of carbonic anhydrase 2 (CA2) was 
reported to cause an autosomal recessive syndrome of RTA, proximal bicarbonate 
wasting, osteopetrosis and cerebral calcification in 1983 [97]. Loss of function 
mutations of the CA2 have been subsequently described [37,91], and nephrocalcinosis 
is reported in these patients [51]. 
 
Miscellaneous 
Amelogenesis Imperfecta with Nephrocalcinosis (AINC) 
AINC is a rare autosomal recessive disorder characterized by dental defects and 
nephrocalcinosis due to mutations in FAM20A [52]. AINC patients are hypocalciuric 
rather than hypercalciuric. FAM20A is a putative kinase in the Golgi apparatus with a 
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proposed role in biomineralisation, hence it’s causality in Amelogenesis and 
nephrocalcinosis [108]. 
 
Medullary Sponge Kidney  
Described by Lenaduzzi in 1939 [61], medullary sponge kidney (MSK) is characterized 
by ectatic precalyceal papillary collecting ducts [38] and causes nephrocalcinosis, 
nephrolithiasis, which may lead to recurrent urosepsis. The condition may be caused 
by disruption to the normal ureteric bed-metanephric interface, which can be 
demonstrated as ectatic precalyceal papillary collecting ducts on intravenous 
pyelography. It has been shown that up to 50% of those with the condition may have 
an affected family member and that a number of these kindreds have inherited MSK 
in an autosomal dominant fashion with variable penetrance [36]. 
During nephrogenesis the metanephric mesenchyme induces ureteric bud growth via 
glial cell-lined derived neurotrophic factor (GDNF) acting on receptor tyrosine kinase 
(RET). Mutations have been found in both of these genes in patients with MSK 
[29,102]. Impaired nephrogenesis may also explain the other tubular defects seen in 
MSK, namely; dRTA, proximal tubular dysfunction, hypercalciuria and hypocitraturia. 
Calcification in MSK takes a number of forms. Apart from simple stones, there are 
ductal stones, ductal and inner medullary collecting duct plugs (which take the shape 
of the tubular segment in which they form, and destroy the epithelium, settling 
eventually on the basement membrane), plug overgrowths, stones growing on 
Randal’s plaques and pelvic stones [34].The dilated collecting ducts and resultant low 
flow contributes to stone formation (especially ductal stones), nephrocalcinosis seems 
to result from ductal plugging and interstitial calcification (e.g. Randal plaques). 
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MSK was classically diagnosed via intravenous urography (IVU), in which the 
diagnosis could be made by the finding of cystic dilations associated with a calyceal 
‘blush’ appearance, caused by pooling of contrast. This would often be in addition to 
the visualization of nephrocalcinosis and nephrolithiasis [38].  
IVUs are no longer available in many centers; and although unenhanced CT scans 
can only confirm nephrocalcinosis, not MSK, more recently, multidetector CT 
urography has been shown to demonstrate the characteristic radiologic findings of 
MSK including medullary cysts, calyceal dilatation, nephrocalcinosis and 
nephrolithiasis [59,71]. 
 
Extra-renal genetic disease causing nephrocalcinosis 
 
Intestinal disease 
Williams’ syndrome 
Williams syndrome (also Williams-Beuren syndrome) is a multisystem disorder 
resulting from the deletion of 26-28 genes from the long arm of chromosome 7[82]. 
The clinical phenotype is of intellectual impairment with a friendly ‘cocktail party’ 
personality, vascular stenosis, characteristic facies and variable hypercalcaemia, 
sometimes with nephrocalcinosis[83], but without either a raised PTH or vitamin D 
level. The specific gene responsible has not been identified; but there is evidence to 
suggest that the Ca2+ channel TRPC3 is up regulated in intestine and kidney and that 
this may be regulated by TF2i, encoded by the transcription factor 2i (GTF2i) gene 
which is located within the deletion on chromosome 7 [62]. 
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Nephrocalcinosis may occur in a number of other monogenic intestinal diseases 
associated with hypercalcaemia/hypercalciuria, such as congenital lactase deficiency 
[86], congenital sucrose/isomaltase deficiency [7], glucose/galactose malabsorption 
[79] and the blue diaper syndrome [30]. 
 
Bone disease 
Primary hyperparathyroidism with Multiple Endocrine Neoplasia type 1 (MEN1) 
MEN1 is an autosomal dominant condition consisting of the strong predisposition to 
form tumors of the parathyroid glands (in over 90% of MEN1 patients over 50), the 
anterior pituitary and the pancreas. The resulting hyperparathyroidism causes 
hypercalcaemia and thus hypercalciuria and subsequent nephrocalcinosis. The 
causative gene is MEN1 [18], which encodes a protein, Menin, which is a putative 
tumor suppressor gene. 
 
Idiopathic Infantile Hypercalcaemia and Hypercalciuric Nephrolithiasis and 
Nephrocalcinosis 
Loss of function mutations of CYP24A1, which encodes the enzyme 1,25-
dihydroxyvitamin D3 24-hydroxylase, cause infantile hypercalcaemia [89] (usually in 
infants who are given vitamin D supplements) and a syndrome of hypercalciuria, 
nephrolithiasis and nephrocalcinosis in patients presenting in later childhood or early 
adulthood [28]. 24-hydroxylase catalyzes the 24 and 23-hydroxylation of 25-(OH)D3 
and 1,25-(OH)2D3, probably in order to regulate and attenuate the action of 1,25-
(OH)2D3 on its target tissues. These autosomal recessive loss of function mutations 
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therefore appear to amplify the effect of native 1,25-(OH)2D3, causing a suppressed 
PTH, hypercalciuria, stones and nephrocalcinosis. 
Other monogenic diseases affecting bone may also cause nephrocalcinosis by 
increasing the urinary concentration of calcium; Neonatal self-limited primary 
hyperparathyroidism [76], Infantile hypophosphatasia [6] and McCune-Albright 
syndrome [56]. 
 
Oxaluria 
Primary Hyperoxaluria types 1, 2 & 3 
Primary hyperoxaluria (PH) is caused by autosomal recessive defects in hepatic 
enzymes involved in the metabolism of glyoxalate, resulting in enhanced oxalate 
production, and thus hyperoxaluria, with subsequent nephrocalcinosis which often 
leads to end-stage renal failure [46]. PH1 is caused by defects in AGXT, which 
encodes peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) which 
converts glyoxylate to glycine [20].  
PH2 is caused by inactivating mutations of GRHPR which encodes cytosolic enzyme 
glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) [90]. The GR/HPR 
enzyme catalyzes the conversion of glyoxalate to glycolate. The increased load of 
glyoxalate is converted by lactate dehydrogenase to oxalate. Mammals cannot 
metabolize oxalate and it must be excreted in the urine. Oxalate is poorly soluble and 
urinary supersaturation leads to both nephrocalcinosis and nephrolithiasis.  
PH3 is caused by genetic inactivation of HOGA1, which encodes the liver-specific 
mitochondrial 4-hydroxy-2-oxoglutarate (HOG) aldolase [8] involved in the final step 
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of hydroxyproline catabolism in mitochondria, catalyzing the cleavage of HOG to 
pyruvate and glyoxalate. The mechanisms by which this impaired catabolism leads to 
oxalate accumulation are, currently, not well understood. PH3 patients typically 
present at a young age with recurrent stone disease, hyperoxaluria and hypercalciuria. 
The disease usually becomes silent in later childhood and does not progress to end 
stage renal failure. 
Most mutations in PH1 patients cause either a complete absence of AGT or abolish 
its function [24,112]. However about a third of patients have presence of functional 
AGT that is mistargeted to the mitochondria rather than peroxisomes. The mistargeting 
is caused by a specific mutation (Gly170Arg), if combined with a common 
polymorphism (Pro11Leu) [84].  Pro11Leu is one of the main allelic variants of the 
AGXT gene; the so-called minor allele with a frequency of about 15 – 20% in European 
and North American individuals. Even in the absence of the Gly170Arg mutation the 
minor allele causes about 5% of AGT to be directed to the mitochondria [84]. It has 
been proposed that this mutation may have arisen through selection pressures of 
particular diets. In carnivores the main precursor of glyoxylate is hydroxyproline, found 
mainly in mitochondria, while in herbivores the precursor is mainly glycolate. Found 
mainly in peroxisomes [50,77]. It is interesting to note that the population with the 
highest frequency of the mutation is the European arctic Sami people (27%), who have 
traditionally had a heavily carnivorous diet. This is in contrast to India, China, and 
Japan where the occurrence is 2-3% [15]. 
 
Acquired 
Hypercalciuria 
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Any condition leading to hypercalciuria can in theory lead to nephrocalcinosis but the 
most common is primary hyperparathyroidism (32% of Wrong’s series [116]). Elevated 
25-OH or 1,25-OH vitamin D levels (both iatrogenic and in granulomatous disease e.g. 
sarcoid) can lead to hypercalcaemia, hypercalciuria and subsequent nephrocalcinosis. 
 
Oxaluria 
Excess oxalate production and oxaluria will lead to a propensity to form calcium 
oxalate crystals. Enteric hyperoxaluria, due to pancreatic insufficiency, small bowel 
resection or calcium restriction may cause nephrocalcinosis [21] by increasing GI 
absorption of oxalate and thus causing hyperoxaluria. Ingestion of ethylene glycol, 
which is metabolized into oxalate, will also cause calcium oxalate precipitation in the 
kidney, either microscopically or macroscopically [99]. 
 
Phosphaturia 
Oral sodium phosphate is sometimes given as bowel preparation before colonoscopy 
or bowel surgery, and may cause massive phosphaturia; renal failure and 
nephrocalcinosis are described [41]. 
 
Acquired tubular defects  
In the loop of Henle, furosemide, a pharmacological inhibitor of NKCC2, can cause 
nephrocalcinosis in adults when taken chronically [55], and when administered to 
neonates and infants [49]. 
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In the collecting duct dRTA causing nephrocalcinosis, may occur with acquired 
disease, notably Sjögren syndrome [42], other autoimmune conditions, (such as 
Lupus) and Wilson disease [47]. 
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Pathophysiological Aspects of Nephrocalcinosis 
Calcium deposition in nephrocalcinosis can take the form of intratubular deposits, 
interstitial deposition (or microliths in the dilated tubules of medullary sponge kidneys).  
 
Intratubular nephrocalcinosis 
Nephrocalcinosis may occur via calcium phosphate or calcium oxalate crystals 
precipitating in the distal nephron when the tubular fluid becomes supersaturated. It is 
likely that a degree of precipitation occurs in tubules of healthy kidneys, however 
healthy tubular epithelial cells present a non-crystal binding surface to the lumen 
[105,106] and a loss of epithelial integrity increases crystal adhesion [105]. Crystal 
nucleation and growth is also inhibited by the urinary environment which is enriched 
with inhibitors of aggregation such as magnesium and Tamm Horsfall protein [32,60].  
Dedifferentiated or regenerating tubular cells express various molecules including 
annexin 2, phosphatidyl serine hyaluronan and osteopontin, that have been shown to 
bind crystals [5,9,17,104].  
Thus a failure of these defense mechanisms, often as a consequence of tubular injury, 
results in epithelial crystal adhesion and possible tubular crystal obstruction if the 
crystal becomes large enough to block the tubular lumen. Tubular obstruction will 
cause a functional loss of the obstructed tubule, presumably with the same sequelae 
that accompany other forms of obstruction. 
Therefore it may be that tubular injury and/or failure of epithelial or of solute defenses 
against crystal nucleation and crystal growth are necessary prerequisites to 
calcification and nephrocalcinosis; perhaps in some part explaining why 
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nephrocalcinosis occurs in some conditions with modest hypercalciuria, and not in 
others in which it is more pronounced.   
 
Interstitial nephrocalcinosis 
Interstitial calcium deposition can either be formed de-novo or can come from 
translocation of intratubular deposits [63].  
Evidence on the initial site of deposition in nephrocalcinosis is lacking, but in stone 
formers with Randall’s plaques (which are exclusively formed of calcium phosphate), 
there is good evidence that the initial calcium phosphate deposition is at the basement 
membrane in the thin limb of the loop of Henle [35]; the basement membrane in the 
thin limb is unusually thick comprising collagen and a large amount of 
mucopolysaccarides [14], which could plausibly offer electrostatically charged sites to 
attract calcium and phosphate, offering a template for crystal formation. As these 
deposits expand by crystal growth, they invade the interstitium, the suburothelial space 
and eventually breach the urothelium [35]. Both inflammation and epithelial cell injury 
are notably absent from the Randall’s plaque type of calcium deposition.  
 
Inflammation and oxalate deposition 
There is growing evidence that oxalate crystals may be pro-inflammatory. This may 
be mediated via their activation of the inflammasome nucleotide-binding domain, 
leucine-rich repeat (NALP-3). An inflammasome is a complex that consists of a sensor 
protein that once stimulated is able to activate the protease caspase-1. Caspase-1 is 
able to then cleave biologically inactive IL-1β and IL-18 to activate them [43,70]. Rats 
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fed an oxalate rich diet develop an interstitial infiltrate associated with calcium oxalate 
crystals and up-regulation of NALP-3 and IL-1β gene expression and associated renal 
failure [57]. Furthermore, NALP-3 null mice had decreased levels on renal 
inflammation and did not develop renal failure despite the presence of calcium oxalate 
crystal deposition [57].  
Thus, it may be the case that in primary hyperoxaluria, inflammation and subsequent 
tubular epithelial damage occurs after calcium oxalate deposition; oxalate 
supersaturation in the proximal tubule as a result of an increased filtered load of 
oxalate in conjunction with active oxalate secretion by proximal tubular cells may 
cause calcium oxalate crystal nucleation and deposition in the S3 segment of the 
proximal tubule. This indeed appeared to be the case in PH1 patients with early 
disease before the onset of renal impairment [114]. 
Calcium phosphate crystals do not seem to induce inflammation in the same way. In 
a biopsy series of patients with calcium oxalate stones associated with Randall’s 
plaques it was shown that even when there was extensive calcium phosphate 
deposition the cells of the associated collecting ducts appeared normal. In contrast, 
patients with crystal deposition directly in the collecting ducts in intestinal bypass 
patients (i.e. calcium oxalate crystals) there was associated fibrosis in the surrounding 
renal tissue [35]. However the same group demonstrated that there is inflammation 
surrounding crystal deposition within the tubules or dRTA patients where the crystals 
are likely to be calcium phosphate [34]. It has also been shown that calcium phosphate 
crystals can activate NALP-3 in vitro [80].  
However, the inflammation associated with oxalate deposition may play an important 
part in the progressive renal failure of primary hyperoxaluria, and indeed the renal 
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dysfunction in other hyperoxaluric states. 
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Clinical Aspects of Nephrocalcinosis 
Clinical features 
Nephrocalcinosis is an insidious process that is usually detected on incidental 
radiological investigation. However, if nephrocalcinosis does cause symptoms, the 
most usual symptom is renal colic, either from associated nephrolithiasis, or possibly 
from the extrusion of an interstitial calcified nodule into a calyx [78]. 
Medullary nephrocalcinosis can cause defects in the function of the distal nephron, 
either distal renal tubular acidosis or diabetes insipidus. Distal renal tubular acidosis 
may be either a cause or a consequence of nephrocalcinosis, and was first described 
by Wrong in a patient who had nephrocalcinosis from vitamin D intoxication [116]. 
Diabetes insipidus leading to a defective urinary concentrating ability may cause 
polyuria and nocturia. These defects may occur due to medullary deposition of calcium 
disrupting the structure and function of the loop of Henle and the medullary collecting 
duct, and may also occur with hypercalcemia, if present [44,113]. 
As nephrocalcinosis develops within the medullary interstitium it causes relative 
hypoxia and inflammation. Polycythemia has been reported in nephrocalcinosis and it 
has been suggested that is in part driven by the hypoxic medulla [1].  
 
Investigations 
By definition, only macroscopic nephrocalcinosis is amenable to imaging diagnosis. 
Nephrocalcinosis can be diagnosed on plain radiographs, ultrasound and CT; 
magnetic resonance imaging is a poor modality to detect calcification [64] 
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Early medullary nephrocalcinosis may be demonstrated as echogenic pyramids 
sonographically before it is visible on a plain film [3,39]; however there may be 
alterations in renal parenchymal echogenicity in a number of different diseases [69]. 
Computed tomography (CT) is the most sensitive modality for imaging calcium, and is 
less operator dependent than ultrasonography. However, a study comparing 
ultrasound and CT in the diagnosis of nephrocalcinosis demonstrated a sensitivity of 
85-91% with ultrasound, 86-92% with CT and only 66-82% with plain kidney-ureter-
bladder (KUB) radiograph [20]. Specificity was best (89%) when ultrasound and CT 
were used together as there is occasionally a lack of concordance in the two 
modalities. Where calcium deposition is seen at papillary tips it is impossible to 
distinguish whether these are due to Randall’s plaques, intra-tubular crystal deposition 
or if these are just calyceal stones [72]. Indeed it has been shown that even when 
there appears to be extensive degrees of nephrocalcinosis on radiological studies 
these may turn out to be nephrolithiasis in the collecting system [72].  
Once the diagnosis of nephrocalcinosis is made, further investigation is warranted to 
determine the underlying cause; as this affects both the management and prognosis.  
Laboratory investigations in a patient with diagnosed nephrocalcinosis are aimed at 
identifying an underlying cause.  
These should include measurement of the serum and urine electrolytes, calcium, 
phosphate and creatinine. As two of the 3 leading causes of nephrocalcinosis are 
hyperparathyroidism and dRTA (the other being MSK) [78], a serum parathyroid 
hormone should be measured to exclude the first and a serum bicarbonate and an 
accurate urine pH to exclude the latter if there is a metabolic acidosis, or a urinary 
acidification test with ammonium chloride [115] or furosemide and fludrocortisone [107], 
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if the serum bicarbonate is in the normal range.  Also, two 24-hour urine collections 
should be made to measure the 24-hour excretion of oxalate, citrate and creatinine. 
 
Clinical course and treatment 
In most cases of nephrocalcinosis the lesion is permanent once present, although in 
rare cases, lessening of medullary nephrocalcinosis has been reported after a 
metabolic defect has been corrected. In most patients, the underlying disease is not 
amenable to treatment and the best that can be achieved is to avoid the 
nephrocalcinosis getting worse. This might be disease specific therapy, such as oral 
alkali supplementation in dRTA (to reduce systemic acidosis, reduce hypercalciuria 
and increase urinary citrate) or liver transplantation in primary hyperoxaluria. 
Generalized measures to reduce hypercalciuria should help slow the deposition of 
parenchymal calcium in most cases, although any evidence for this is conspicuously 
lacking; this could involve dietary restriction of sodium and the administration of 
thiazide diuretics. 
Progressive renal failure is typical in mainly four of the diseases that cause 
nephrocalcinosis, primary hyperoxaluria, familial hypomagnesemia with hypercalciuria 
and nephrocalcinosis, Dent disease and Lowe syndrome. These patients need 
counseling and appropriate monitoring. 
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Conclusion 
Medullary nephrocalcinosis is a relatively frequent finding in nephrological practice. 
Although nephrocalcinosis can cause a number of clinical problems, progressive renal 
failure is an uncommon complication in the absence of obstructing stone disease. Pain 
and recurrent infection are more likely, if symptoms are present at all. 
While nephrocalcinosis occurs within a wide spectrum of pathophysiology, the 
commonest three causes in adults are primary hyperparathyroidism, distal renal 
tubular acidosis and medullary sponge kidney, in that order [116]. Knowledge of the 
systemic and renal specific causes of nephrocalcinosis will help to identify the primary 
lesion, be it genetic, or acquired. As some may cause ESRF, and others may cause 
systemic disease, making a diagnosis is clinically important.  
Our understanding of the pathophysiology behind many of the genetic conditions 
associated with nephrocalcinosis has advanced significantly over recent decades. 
There are however many unanswered questions: Why are some forms of 
nephrocalcinosis associated with progressive CKD and others not? Why do some 
patients with hypercalciuria consistently fail to develop nephrocalcinosis while others 
often with lower urinary calcium concentrations do? What is the mechanism of 
nephrocalcinosis in insulin receptor mutations? And what are the exact molecular 
players in proximal calcium reabsorption? 
Further investigation into these questions concerning renal calcification may lead to 
greater understanding not only of the physiology of the kidney, but perhaps also to the 
phenomena of ectopic calcification elsewhere and, eventually, to better treatments. 
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Figure Legends 
 
Figure 1.  
A plain abdominal radiograph showing severe medullary nephrocalcinosis. 
 
Figure 2. 
Abdominal ultrasound examination showing a kidney in longitudinal view in a child with 
Bartter’s. The calcified areas of the medulla are echogenic and clearly visible. 
 
Figure 3. 
Diagram showing sites of calcium reabsorption through the nephron.  
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Table 1 
LOCATION Disease Gene Gene Product Inheritance Phenotype/ 
Remarks 
SYSTEMIC  
DISEASES 
William’s Syndrome GTF2i 
(speculated) 
TF2i (regulates TRPC3 
calcium channel in the 
intestine) 
Sporadic Hypercalciuria 
Multisystem 
condition; 
likely multiple 
genes involved  
 Multiple Endocrine 
Neoplasia Type 1 
MEN1 Menin Autosomal Dominant  Hypercalciuria  
 Idiopathic Infantile 
Hypercalcaemia  
CYP24A1 1,25-dihydroxyvitamin D3 24-
hydroylase 
Autosomal Recessive Hypercalciuria  
 Primary 
Hyperoxaluria 
types1,2,&3 
AGXT, 
GRHPR, 
HOGA1 
respectively 
Alanine:glyoxylate 
aminotransferase, glyoylate 
reductase/hydroxypyruvate 
reductase, mitochondrial 4-
hydoxy-2-oxoglutarate 
aldolase respectively 
Autosomal Recessive Hyperoxaluria. 
Associated 
with ERSF 
PROXIMAL 
TUBULE 
Dent’s Disease CLCN5 CIC-5 X-linked recessive Hypercalciuria.
Associated 
with ESRF 
Fanconi like 
phenotype 
 Lowe Syndrome OCRL1 PIP2 5-phosphatase X-linked recessive Hypercalciuria
Associated 
with cataracts 
and mental 
impairment 
 Idiopathic Infantile 
Hypercalciuria 
SLC34A1 NaPi2a Autosomal recessive Hypercalciuria 
 Hereditary 
Hypophosphatemia 
and 
Nephrocalcinosis  
SLC34A3 NaPi2c Autosomal recessive Hypercalciuria 
 Fanconi Bickel 
Syndrome 
SLC2A2 GLUT2 Autosomal Recessive Hypercalciuria  
LOOP of HENLE Bartter Syndromes 
(Types I-IV) 
SLC12A1, 
KCNJ1, 
CLCNKB, 
BSND 
NKCC2, ROMK, CLCKb, Barttin Autosomal Recessive Hypercalciuria 
Type IV 
associated with 
sensorineural 
deafness  
 Familial 
Hypomagnesemia 
with Hypercalciuria 
and 
Nephrocalcinosis 
CLDN 14 
CLDN16 
CLDN19 
Claudin-16, Claudin-19 
 
Claudin-14 
Autosomal Recessive Hypercalciuria
Associated 
with ESRF 
Hypercalciuria 
and kidney 
stones. 
Sensorineural 
deafness 
 Insulin Receptor 
Mutations 
Insulin 
Receptor 
Gene 
Insulin Receptor Autosomal Recessive  
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CORTICAL 
COLLECTING 
DUCT 
Distal Renal Tubular 
Acidosis 
ATP6V1V1, 
ATP6V0A4 
 
 
SLC4A1 
 
 
 
CA2 
B-subtype unit and a-subtype 
unit respectively of 
H(+)ATPase 
 
AE1 
 
 
 
Carbonic Anhydrase  
Autosomal Recessive 
 
 
Autosomal 
Dominant/Recessive 
 
 
Autosomal Recessive 
Associated 
with 
sensorineural 
deafness 
 
 
 
 
Associated 
with co-
existing 
proximal 
defect  
MISCELANEOUS Medullary Sponge 
Kidney 
RET and 
GDNF genes 
(speculated) 
RET & GDNF Autosomal dominant 
with variable 
penetrance 
Hypercalciuria 
hypocitraturia 
 Amelogenesis 
Imperfecta with 
Nephrocalcinosis 
FAM20A Putative kinase in Golgi 
apparatus 
Autosomal Recessive Hypocalciuria 
Associated 
with dental 
defects  
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Table Legend 
Table 1.  
Familial diseases leading to nephrocalcinosis 
 
 
 
